Clinical Characteristics of Membranous Nephropathy After Allogeneic Hematopoietic Stem Cell Transplantation: A real-world Multicenter Study

Overview

Journal Ann Hematol

Specialty Hematology

Date 2024 Jul 11

PMID 38990296

Authors

Yue Jin

Peng Zhao

Yuan-Yuan Zhang

Yi-Shan Ye

Fang Zhou

Ding-Ming Wan

Yi Chen

Jian Zhou

Xin Li

Yan Wang

Yue Liu

Zhi-Lei Bian

Kai-Qian Yang

Zhen Li

Jian Zhang

Wen-Wei Xu

Jian-Ying Zhou

Zhuo-Yu An

Hai-Xia Fu

Yu-Hong Chen

Qi Chen

Jin Wu

Jing-Zhi Wang

Xiao-Dong Mo

Huan Chen

Yao Chen

Yu Wang

Ying-Jun Chang

He Huang

Xiao-Jun Huang

Xiao-Hui Zhang

Affiliations

Soon will be listed here.

Abstract

Membranous nephropathy (MN) is a rare complication that can occur after allogeneic hematopoietic stem cell transplantation (allo-HSCT). MN patients may develop nephrotic syndrome or even kidney failure, which greatly affects their quality of life and prognosis. However, current knowledge regarding MN after allo-HSCT is limited. Thus, a multicenter nested case‒control study was conducted. Patients who had been diagnosed with MN after allo-HSCT were retrospectively identified at 8 HSCT centers. A total of 51 patients with MN after allo-HSCT were included. The median age of MN patients after allo-HSCT was 38 years, and the median duration from HSCT to MN was 18 months. The use of HLA-matched donors (P = 0.0102) and peripheral blood as the graft source (P = 0.0060) were identified as independent predisposing risk factors for the onset of MN after allo-HSCT. Compared to those in the control group, the incidence of extensive chronic graft-versus-host disease was greater in the MN patients (P = 0.0002). A total of 31 patients developed nephrotic syndrome. Patients receiving combination treatments of corticosteroids and immunosuppressants appeared to have better outcomes. In conclusion, MN is a rare but occasionally severe complication following HSCT and may require active treatment.

References

Zhang X, Chen J, Han M, Huang H, Jiang E, Jiang M . The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update. J Hematol Oncol. 2021; 14(1):145. PMC: 8441240. DOI: 10.1186/s13045-021-01159-2. View

Troxell M, Pilapil M, Miklos D, Higgins J, Kambham N . Renal pathology in hematopoietic cell transplantation recipients. Mod Pathol. 2008; 21(4):396-406. DOI: 10.1038/modpathol.3801011. View

Hu S . The role of graft-versus-host disease in haematopoietic cell transplantation-associated glomerular disease. Nephrol Dial Transplant. 2010; 26(6):2025-31. DOI: 10.1093/ndt/gfq645. View

Grubbs V . ESRD and Hospice Care in the United States: Are Dialysis Patients Welcome?. Am J Kidney Dis. 2018; 72(3):429-432. DOI: 10.1053/j.ajkd.2018.04.008. View

Jagasia M, Greinix H, Arora M, Williams K, Wolff D, Cowen E . National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2014; 21(3):389-401.e1. PMC: 4329079. DOI: 10.1016/j.bbmt.2014.12.001. View

Byrne-Dugan C, Collins A, Lam A, Batal I . Membranous nephropathy as a manifestation of graft-versus-host disease: association with HLA antigen typing, phospholipase A2 receptor, and C4d. Am J Kidney Dis. 2014; 64(6):987-93. DOI: 10.1053/j.ajkd.2014.09.001. View

Terrier B, Delmas Y, Hummel A, Presne C, Glowacki F, Knebelmann B . Post-allogeneic haematopoietic stem cell transplantation membranous nephropathy: clinical presentation, outcome and pathogenic aspects. Nephrol Dial Transplant. 2007; 22(5):1369-76. DOI: 10.1093/ndt/gfl795. View

Niscola P, Tendas A, Luo X, Catalano G, Scaramucci L, Cupelli L . The Management of Membranous Glomerulopathy in Allogeneic Stem Cells Transplantation: Updated Literature. Cardiovasc Hematol Agents Med Chem. 2012; 11(1):67-76. DOI: 10.2174/1871525711311010011. View

Dhakal B, Singavi A, Cohen E, Dangal M, Palmer J, Dall A . Chronic GVHD and concurrent new-onset nephrotic syndrome in allogeneic transplant recipients. Incidence, pattern and therapeutic outcomes. Bone Marrow Transplant. 2014; 50(3):449-51. DOI: 10.1038/bmt.2014.261. View

10.

Colombo A, Rusconi C, Esposito C, Bernasconi P, Caldera D, Lazzarino M . Nephrotic syndrome after allogeneic hematopoietic stem cell transplantation as a late complication of chronic graft-versus-host disease. Transplantation. 2006; 81(8):1087-92. DOI: 10.1097/01.tp.0000209496.26639.cb. View

11.

Beyar-Katz O, Davila E, Zuckerman T, Fineman R, Haddad N, Okasha D . Adult Nephrotic Syndrome after Hematopoietic Stem Cell Transplantation: Renal Pathology is the Best Predictor of Response to Therapy. Biol Blood Marrow Transplant. 2016; 22(6):975-981. DOI: 10.1016/j.bbmt.2015.12.014. View

12.

Hiramatsu R, Ubara Y, Sawa N, Hasegawa E, Kawada M, Imafuku A . Clinicopathological analysis of allogeneic hematopoietic stem cell transplantation-related membranous glomerulonephritis. Hum Pathol. 2016; 50:187-94. DOI: 10.1016/j.humpath.2015.12.005. View

13.

Nasr S, Leung N, Said S, Alkhateeb H, Madden B, Charlesworth M . Membranous Nephropathy With Extensive Tubular Basement Membrane Deposits Following Allogeneic Hematopoietic Cell Transplant: A Report of 5 Cases. Am J Kidney Dis. 2021; 79(6):904-908. DOI: 10.1053/j.ajkd.2021.07.021. View

14.

Sethi S, Madden B, Casal Moura M, Nasr S, Klomjit N, Gross L . Hematopoietic Stem Cell Transplant-Membranous Nephropathy Is Associated with Protocadherin FAT1. J Am Soc Nephrol. 2022; 33(5):1033-1044. PMC: 9063902. DOI: 10.1681/ASN.2021111488. View

15.

Ronco P, Debiec H . Pathogenesis of membranous nephropathy: recent advances and future challenges. Nat Rev Nephrol. 2012; 8(4):203-13. DOI: 10.1038/nrneph.2012.35. View

16.

Huang X, Qin W, Zhang M, Zheng C, Zeng C, Liu Z . Detection of anti-PLA2R autoantibodies and IgG subclasses in post-allogeneic hematopoietic stem cell transplantation membranous nephropathy. Am J Med Sci. 2012; 346(1):32-7. DOI: 10.1097/MAJ.0b013e318267b5cd. View

17.

Kodner C . Diagnosis and Management of Nephrotic Syndrome in Adults. Am Fam Physician. 2016; 93(6):479-85. View

18.

Ferrannini M, Vischini G, Di Daniele N . Rituximab in membranous nephropathy after haematopoietic stem cell transplantation. Nephrol Dial Transplant. 2008; 23(8):2700-1. DOI: 10.1093/ndt/gfn110. View

19.

Vischini G, Cudillo L, Ferrannini M, Di Daniele N, Cerretti R, Arcese W . Rituximab in post allogeneic hematopoietic stem cell transplantation membranous nephropathy: a case report. J Nephrol. 2009; 22(1):160-3. View

20.

Mattei D, Sorasio R, Guarnieri A, Marazzi F, Formica M, Fortunato M . Long-term results of rituximab treatment for membranous nephropathy after allogeneic hematopoietic SCT: a case report. Bone Marrow Transplant. 2009; 45(6):1111-2. DOI: 10.1038/bmt.2009.276. View